×
QQQ   283.54 (-3.05%)
AAPL   137.44 (-2.98%)
MSFT   256.48 (-3.17%)
META   160.68 (-5.20%)
GOOGL   2,240.15 (-3.30%)
AMZN   107.40 (-5.14%)
TSLA   697.99 (-5.00%)
NVDA   159.82 (-5.26%)
NIO   22.36 (-2.57%)
BABA   116.76 (-1.66%)
AMD   80.78 (-6.24%)
MU   57.86 (-1.57%)
CGC   3.61 (-4.75%)
T   20.61 (-0.82%)
GE   65.88 (-1.24%)
F   11.81 (-1.91%)
DIS   95.92 (-0.71%)
AMC   13.38 (-5.31%)
PFE   50.66 (-2.35%)
PYPL   71.82 (-5.43%)
NFLX   179.60 (-5.04%)
QQQ   283.54 (-3.05%)
AAPL   137.44 (-2.98%)
MSFT   256.48 (-3.17%)
META   160.68 (-5.20%)
GOOGL   2,240.15 (-3.30%)
AMZN   107.40 (-5.14%)
TSLA   697.99 (-5.00%)
NVDA   159.82 (-5.26%)
NIO   22.36 (-2.57%)
BABA   116.76 (-1.66%)
AMD   80.78 (-6.24%)
MU   57.86 (-1.57%)
CGC   3.61 (-4.75%)
T   20.61 (-0.82%)
GE   65.88 (-1.24%)
F   11.81 (-1.91%)
DIS   95.92 (-0.71%)
AMC   13.38 (-5.31%)
PFE   50.66 (-2.35%)
PYPL   71.82 (-5.43%)
NFLX   179.60 (-5.04%)
QQQ   283.54 (-3.05%)
AAPL   137.44 (-2.98%)
MSFT   256.48 (-3.17%)
META   160.68 (-5.20%)
GOOGL   2,240.15 (-3.30%)
AMZN   107.40 (-5.14%)
TSLA   697.99 (-5.00%)
NVDA   159.82 (-5.26%)
NIO   22.36 (-2.57%)
BABA   116.76 (-1.66%)
AMD   80.78 (-6.24%)
MU   57.86 (-1.57%)
CGC   3.61 (-4.75%)
T   20.61 (-0.82%)
GE   65.88 (-1.24%)
F   11.81 (-1.91%)
DIS   95.92 (-0.71%)
AMC   13.38 (-5.31%)
PFE   50.66 (-2.35%)
PYPL   71.82 (-5.43%)
NFLX   179.60 (-5.04%)
QQQ   283.54 (-3.05%)
AAPL   137.44 (-2.98%)
MSFT   256.48 (-3.17%)
META   160.68 (-5.20%)
GOOGL   2,240.15 (-3.30%)
AMZN   107.40 (-5.14%)
TSLA   697.99 (-5.00%)
NVDA   159.82 (-5.26%)
NIO   22.36 (-2.57%)
BABA   116.76 (-1.66%)
AMD   80.78 (-6.24%)
MU   57.86 (-1.57%)
CGC   3.61 (-4.75%)
T   20.61 (-0.82%)
GE   65.88 (-1.24%)
F   11.81 (-1.91%)
DIS   95.92 (-0.71%)
AMC   13.38 (-5.31%)
PFE   50.66 (-2.35%)
PYPL   71.82 (-5.43%)
NFLX   179.60 (-5.04%)
LON:HCM

HUTCHMED Share Forecast, Price & News

GBX 219
+4.00 (+1.86%)
(As of 06/28/2022 12:00 AM ET)
Add
Compare
Today's Range
215.50
222.50
50-Day Range
144
268
52-Week Range
137.80
656
Volume
26,955 shs
Average Volume
115,118 shs
Market Capitalization
£1.89 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
GBX 220
30 days | 90 days | 365 days | Advanced Chart

Receive HCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HUTCHMED and its competitors with MarketBeat's FREE daily newsletter.

HCM Stock Forecast (MarketRank)

Overall MarketRank

1.30 out of 5 stars

Analyst Opinion: 1.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
HUTCHMED logo

About HUTCHMED (LON:HCM)

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.

HCM Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Drug Manufacturers - Major
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
1,760
Year Founded
N/A

Company Calendar

Today
6/28/2022
Next Earnings (Estimated)
8/01/2022

Price Target and Rating

Average Stock Price Forecast
GBX 220
High Stock Price Forecast
GBX 220
Low Stock Price Forecast
GBX 220
Forecasted Upside/Downside
+0.5%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£356.13 million
Cash Flow
GBX 117.96 per share
Book Value
GBX 115.20 per share

Miscellaneous

Free Float
N/A
Market Cap
£1.89 billion
Optionable
Not Optionable
Beta
N/A














HUTCHMED Frequently Asked Questions

Should I buy or sell HUTCHMED stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HUTCHMED in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" HUTCHMED stock.
View analyst ratings for HUTCHMED
or view top-rated stocks.

What is HUTCHMED's stock price forecast for 2022?

1 brokerages have issued 12 month price objectives for HUTCHMED's shares. Their HCM stock forecasts range from GBX 220 to GBX 220. On average, they anticipate HUTCHMED's share price to reach GBX 220 in the next twelve months. This suggests a possible upside of 0.5% from the stock's current price.
View analysts' price targets for HUTCHMED
or view top-rated stocks among Wall Street analysts.

How has HUTCHMED's stock price performed in 2022?

HUTCHMED's stock was trading at GBX 530 at the beginning of 2022. Since then, HCM shares have decreased by 58.7% and is now trading at GBX 219.
View the best growth stocks for 2022 here
.

When is HUTCHMED's next earnings date?

HUTCHMED is scheduled to release its next quarterly earnings announcement on Monday, August 1st 2022.
View our earnings forecast for HUTCHMED
.

Who are HUTCHMED's key executives?

HUTCHMED's management team includes the following people:
  • Mr. Chi Keung To ACGI, B.Sc., BSc, M.B.A., MBA, Exec. Chairman (Age 70, Pay $85k)
  • Dr. Weiguo Su B.Sc., Ph.D., CEO, Chief Scientific Officer & Exec. Director (Age 65, Pay $1.36M)
  • Mr. Chig Fung Cheng BEc, CA, CFO & Exec. Director (Age 55, Pay $838.51k)
  • Ms. Edith Shih C.S., CGP, FCS, M.A., P.E., BSE, EdM, Solicito, Company Sec. & Non-Exec. Director (Age 70, Pay $74.3k)
  • Dr. Karen Jane Atkin, Exec. VP & COO (Age 56)
  • Mr. Kin Hung Lee M.B.A., Sr. VP of Corp. Fin. & Devel. (Age 45)
  • Mr. Charles George Rupert Nixon, Group Gen. Counsel (Age 52)
  • Ms. Selina Zhang, Sr. VP of Global HR
  • Dr. Qingmei Wang Ph.D., Sr. VP of Bus. Devel. & Strategic Alliances (Age 59)
  • Mr. Hong Chen, Sr. VP & Chief Commercial Officer- China (Age 52)

What other stocks do shareholders of HUTCHMED own?

Based on aggregate information from My MarketBeat watchlists, some companies that other HUTCHMED investors own include Intelsat (I), Associated British Foods (ABF), Fossil Group (FOSL), Chaarat Gold (CGH), AMC Entertainment (AMC), Bank of America (BAC), First Data (FDC), Air Canada (AC), Apollo Global Management (APO) and China Unicom (Hong Kong) (CHU).

What is HUTCHMED's stock symbol?

HUTCHMED trades on the London Stock Exchange (LON) under the ticker symbol "HCM."

How do I buy shares of HUTCHMED?

Shares of HCM and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is HUTCHMED's stock price today?

One share of HCM stock can currently be purchased for approximately GBX 219.

How much money does HUTCHMED make?

HUTCHMED (LON:HCM) has a market capitalization of £1.89 billion and generates £356.13 million in revenue each year.

How many employees does HUTCHMED have?

HUTCHMED employs 1,760 workers across the globe.

How can I contact HUTCHMED?

The official website for HUTCHMED is www.chi-med.com. The company can be reached via phone at +85221213888.

This page (LON:HCM) was last updated on 6/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.